Arix Bioscience kicks off trading on London Stock Exchange

Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, said: “We are delighted to commence trading on the London Stock Exchange and thank all existing shareholders for their support and welcome new shareholders to our register.  We look forward to delivering medical innovation around the globe for patients and to unlocking significant value for investors.”

Arix Bioscience said last week on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.